Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

163 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial.
Hall FC, Cheriyan J, Cope AP, Galloway J, Wilkinson I, Bond S, Norton S, Banham-Hall E, Bayes H, Kostapanos M, Nodale M, Petchey WG, Sheeran T, Underwood J, Jayne DR; TACTIC-R Investigators Group. Hall FC, et al. Among authors: cope ap. Lancet Respir Med. 2023 Dec;11(12):1064-1074. doi: 10.1016/S2213-2600(23)00376-4. Epub 2023 Nov 14. Lancet Respir Med. 2023. PMID: 37977159 Free PMC article. Clinical Trial.
Cure as a treatment target in rheumatoid arthritis and systemic sclerosis-achievable aim or mission impossible? FOREUM stimulates new industry-academia collaboration.
Baker KF, Spierings J, Brom M, Radstake T, Smith E, Weiss R, Burmester GR; FOREUM Boot Camp Working Group member. Baker KF, et al. Ann Rheum Dis. 2024 Nov 12:ard-2024-226772. doi: 10.1136/ard-2024-226772. Online ahead of print. Ann Rheum Dis. 2024. PMID: 39532310 Free article. No abstract available.
Temporal and regional variation in the use of biologic and targeted synthetic DMARDs for rheumatoid arthritis: a nationwide cohort study.
Russell MD, Yang Z, Dooley N, Gibson M, Zuckerman B, Adas MA, Alveyn E, Patel S, Bechman K, Price E, Gallagher S, Coalwood C, Cope AP, Norton S, Galloway JB. Russell MD, et al. Among authors: cope ap. Rheumatology (Oxford). 2024 Nov 1:keae607. doi: 10.1093/rheumatology/keae607. Online ahead of print. Rheumatology (Oxford). 2024. PMID: 39485485
Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national cohort study.
Russell MD, Gibson M, Zuckerman B, Kumar K, Dubey S, Adas MA, Alveyn E, Patel S, Yang Z, Bechman K, Price E, Gallagher S, Cope AP, Norton S, Galloway JB. Russell MD, et al. Among authors: cope ap. Lancet Rheumatol. 2024 Oct 15:S2665-9913(24)00221-2. doi: 10.1016/S2665-9913(24)00221-2. Online ahead of print. Lancet Rheumatol. 2024. PMID: 39423845 Free article.
Therapeutic interception in individuals at risk of rheumatoid arthritis to prevent clinically impactful disease.
Deane KD, Holers VM, Emery P, Mankia K, El-Gabalawy H, Sparks JA, Costenbader KH, Schett G, van der Helm-van Mil A, van Schaardenburg D, Thomas R, Cope AP. Deane KD, et al. Among authors: cope ap. Ann Rheum Dis. 2024 Sep 24:ard-2023-224211. doi: 10.1136/ard-2023-224211. Online ahead of print. Ann Rheum Dis. 2024. PMID: 39242182 Free article. Review.
Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial.
Cope AP, Jasenecova M, Vasconcelos JC, Filer A, Raza K, Qureshi S, D'Agostino MA, McInnes IB, Isaacs JD, Pratt AG, Fisher BA, Buckley CD, Emery P, Ho P, Buch MH, Ciurtin C, van Schaardenburg D, Huizinga T, Toes R, Georgiou E, Kelly J, Murphy C, Prevost AT; APIPPRA study investigators. Cope AP, et al. Lancet. 2024 Mar 2;403(10429):838-849. doi: 10.1016/S0140-6736(23)02649-1. Epub 2024 Feb 13. Lancet. 2024. PMID: 38364839 Free article. Clinical Trial.
The influence of safety warnings on the prescribing of JAK inhibitors.
Russell MD, Yang Z, Walter B, Alveyn E, Bechman K, Miracle A, Nagra D, Adas MA, Norton S, Cope AP, Langan SM, Galloway JB. Russell MD, et al. Among authors: cope ap. Lancet Rheumatol. 2024 Mar;6(3):e138-e139. doi: 10.1016/S2665-9913(24)00002-X. Epub 2024 Feb 1. Lancet Rheumatol. 2024. PMID: 38310922 No abstract available.
Gout incidence and management during the COVID-19 pandemic in England, UK: a nationwide observational study using OpenSAFELY.
Russell MD, Massey J, Roddy E, MacKenna B, Bacon S, Goldacre B, Andrews CD, Hickman G, Mehrkar A, Mahto A, Rutherford AI, Patel S, Adas MA, Alveyn E, Nagra D, Bechman K, Ledingham JM, Hudson J, Norton S, Cope AP, Galloway JB. Russell MD, et al. Among authors: cope ap. Lancet Rheumatol. 2023 Oct;5(10):e622-e632. doi: 10.1016/S2665-9913(23)00206-0. Epub 2023 Aug 31. Lancet Rheumatol. 2023. PMID: 38251486 Free PMC article.
Implementing treat-to-target urate-lowering therapy during hospitalizations for gout flares.
Russell MD, Ameyaw-Kyeremeh L, Dell'Accio F, Lapham H, Head N, Stovin C, Patel V, Clarke BD, Nagra D, Alveyn E, Adas MA, Bechman K, de la Puente MA, Ellis B, Byrne C, Patel R, Rutherford AI, Cantle F, Norton S, Roddy E, Hudson J, Cope AP, Galloway JB. Russell MD, et al. Among authors: cope ap. Rheumatology (Oxford). 2024 Aug 1;63(8):2222-2229. doi: 10.1093/rheumatology/kead574. Rheumatology (Oxford). 2024. PMID: 37929968 Free PMC article.
163 results